OAM
HZNP

Ostrum Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ostrum Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,420
Closed -$511K – 682
2023
Q3 		$511K Sell
4,420
-31
-0.7% -$3.33K 0.05% 436
2023
Q2 		$458K Buy
4,451
+4
+0.1% +$422 0.04% 446
2023
Q1 		$485K Buy
+4,447
New +$492K 0.04% 428

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Ostrum Asset Management's HZNP Position: Q4 2023 in Review

Ostrum Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,420 shares — an estimated $511K sold.

Ostrum Asset Management first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $511K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Ostrum Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Ostrum Asset Management sold 4,420 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $511K.
  • Ostrum Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Ostrum Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $511K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Ostrum Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.